News
Don’t Fry Day: Today & Everyday
27 May 2022 In Allies & Partnerships, Events
Each year the National Council on Skin Cancer Prevention designates the Friday before Memorial Day as Don’t Fry Day to raise awareness of the importance of sun safety. This year’s theme, Small Steps for Sun Safety, highlights the many small steps we can take to be more sun safe, like...
What Melanoma Patients Need to Know about Opdualag
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 May 2022 In Science, Treatment
You may have heard of Opdualag, a new therapy that recently earned FDA approval for advanced melanoma. Opdualag, which combines two different immunotherapies into one medicine, is earning attention as an effective – and more easily tolerated – combination therapy.
MRA Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 19 May 2022 In News, Prevention, Science, Treatment
Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment.
The Melanoma Research Alliance Names Dr. Marc Hurlbert as Chief Executive Officer
11 May 2022 In Allies & Partnerships, News
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced that its Board of Directors appointed Marc Hurlbert, PhD, as its new Chief Executive Officer.
Dr. Gary Deng & The Wellness Principles
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 9 May 2022 In Allies & Partnerships, Prevention, Treatment
Gary Deng, MD, PhD – an integrative medicine specialist at Memorial Sloan Kettering Cancer Center – knows this firsthand. And now, for the first time, Dr. Deng is sharing his unique and highly respected wellness approach with everyone through his upcoming book, The Wellness Principles – Cooking for a Healthy Life.
Why I Step - Lynn Merrill Iverson
By Renee Orcione, MRA Digital Engagement & Communications Manager | 25 April 2022 In Allies & Partnerships, Events, Melanoma Stories
In 2021, as part of MRA’s inaugural Step Up for Melanoma challenge, Lynn joined hundreds of supportive and passionate individuals across the country to share Bert’s story, keep his memory alive, raise awareness, and complete 310,000 steps during Melanoma Awareness Month.
A Message from the Melanoma Research Alliance
21 April 2022 In News
Michael Kaplan, MRA’s President & CEO, will retire on April 30, 2022. Kaplan, who has led the Melanoma Research Alliance since 2016, will be succeeded by Dr. Marc Hurlbert.
What You Control: Your Microbiome, Diet, Stress, & Melanoma
14 April 2022 In Science
Every day, we hear from patients who want to know what, if anything, they can do to have the best health outcomes possible. For people facing melanoma, it’s common to feel overwhelmed and out of control with everything that a melanoma diagnosis and treatment entail. Yet, how one faces those challenges, can make a big difference. MRA-funded investigator Lorenzo Cohen, PhD is working hard to help patients understand the pivotal role of the microbiome, diet, stress — and their melanoma — on treatment outcomes.
Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment
It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.
MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma
18 March 2022 In News, Science, Treatment
The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.